Top

International Journal of Clinical Oncology

Published in:

01-04-2017 | Invited Review Article

Biomarkers for precision medicine in bladder cancer

Authors: Takahiro Kojima, Koji Kawai, Jun Miyazaki, Hiroyuki Nishiyama

Published in: International Journal of Clinical Oncology | Issue 2/2017

Abstract

Bladder cancer (BC) is classified as non-muscle-invasive BC (NMIBC) or muscle-invasive BC (MIBC). Because the recurrence and mortality rates of BC are high, suitable biomarkers for early detection, evaluation of prognosis, and surveillance of drug responses are needed. Urinary markers simplify surveillance schedules and improve early detection of tumors, especially in NMIBC. Various markers have been identified at DNA, RNA, and protein levels with different sensitivities and specificities. Several biomarkers show a higher sensitivity than urinary cytology, but they are not accurate enough to replace it. In terms of prediction of clinical outcome and treatment response of BC, conventional clinical and pathological parameters are widely used, but the predictive ability of these parameters is limited; therefore, molecular biomarkers in this field are strongly desired. Molecular profiling using fluid and tissue is becoming more feasible with recent developments in next-generation sequencing technologies. Currently, these profiling methods are beginning to be used for early detection, prediction of prognosis, and drug sensitivity. Furthermore, several groups used transcriptome profiling to classify MIBC into various distinct subtypes, showing distinct clinical behaviors and responses to chemotherapy and immune checkpoint inhibitors. The aim of this review is to provide a summary of the most relevant biomarkers that have been investigated as diagnostic and prognostic indicators of BC.

Ferlay J, Soerjomataram I, Dikshit R et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E386. doi:10.1002/ijc.29210 CrossRefPubMed

Yafi FA, Brimo F, Steinberg J et al (2015) Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer. Urol Oncol 33(2):66.e25–e31. doi:10.1016/j.urolonc.2014.06.008

Rosser CJ, Chang M, Dai Y et al (2014) Urinary protein biomarker panel for the detection of recurrent bladder cancer. Cancer Epidemiol Biomarkers Prev 23(7):1340–1345. doi:10.1158/1055-9965.EPI-14-0035 CrossRefPubMedPubMedCentral

Lotan Y, Roehrborn CG (2003) Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology 61(1):109–118CrossRefPubMed

Grossman HB, Messing E, Soloway M et al (2005) Detection of bladder cancer using a point-of-care proteomic assay. JAMA 293(7):810–816CrossRefPubMed

Shariat SF, Savage C, Chromecki TF et al (2011) Assessing the clinical benefit of nuclear matrix protein 22 in the surveillance of patients with nonmuscle-invasive bladder cancer and negative cytology: a decision-curve analysis. Cancer 117(13):2892–2897. doi:10.1002/cncr.25903 CrossRefPubMedPubMedCentral

Ho CC, Tan WP, Pathmanathan R et al (2013) Fluorescence-in situ-hybridization in the surveillance of urothelial cancers: can use of cystoscopy or ureteroscopy be deferred? Asian Pac J Cancer Prev 14(7):4057–4059CrossRefPubMed

Black PC, Brown GA, Dinney CP (2006) Molecular markers of urothelial cancer and their use in the monitoring of superficial urothelial cancer. J Clin Oncol 24(35):5528–5535CrossRefPubMed

Yoder BJ, Skacel M, Hedgepeth R et al (2007) Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings. Am J Clin Pathol 127(2):295–301CrossRefPubMed

10.

Hajdinjak T (2008) UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing. Urol Oncol 26(6):646–651. doi:10.1016/j.urolonc.2007.06.002 CrossRefPubMed

11.

Lokeshwar VB, Habuchi T, Grossman HB et al (2005) Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology 66:35–63CrossRefPubMed

12.

Whitson J, Berry A, Carroll P et al (2009) A multicolour fluorescence in situ hybridization test predicts recurrence in patients with high-risk superficial bladder tumours undergoing intravesical therapy. BJU Int 104(3):336–339. doi:10.1111/j.1464-410X.2009.08375.x CrossRefPubMed

13.

Savic S, Zlobec I, Thalmann GN et al (2009) The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guerin therapy. Int J Cancer 124(12):2899–2904. doi:10.1002/ijc.24258 CrossRefPubMed

14.

Griffiths-Jones S, Grocock RJ, van Dongen S et al (2006) microRNA sequences, targets and gene nomenclature. Nucleic Acids Res 34:D140–D144CrossRefPubMed

15.

Yoshino H, Seki N, Itesako T et al (2013) Aberrant expression of microRNAs in bladder cancer. Nat Rev Urol 10(7):396–404. doi:10.1038/nrurol.2013.113 CrossRefPubMed

16.

Cheng Y, Deng X, Yang X et al (2015) Urine microRNAs as biomarkers for bladder cancer: a diagnostic meta-analysis. Onco Targets Therapy 8:2089–2096. doi:10.2147/OTT.S86908

17.

Chen L, Cui Z, Liu Y et al (2015) MicroRNAs as biomarkers for the diagnostics of bladder cancer: a meta-analysis. Clin Lab 61(8):1101–1108PubMed

18.

Clark SJ, Melki J (2002) DNA methylation and gene silencing in cancer: which is the guilty party? Oncogene 21(35):5380–5387CrossRefPubMed

19.

Dhawan D, Hamdy FC, Rehman I et al (2006) Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma. J Pathol 209(3):336–343CrossRefPubMed

20.

Kandimalla R, van Tilborg AA, Zwarthoff EC (2013) DNA methylation-based biomarkers in bladder cancer. Nat Rev Urol 10(6):327–335. doi:10.1038/nrurol.2013.89 CrossRefPubMed

21.

Phe V, Cussenot O, Roupret M (2009) Interest of methylated genes as biomarkers in urothelial cell carcinomas of the urinary tract. BJU Int 104(7):896–901. doi:10.1111/j.1464-410X.2009.08696.x CrossRefPubMed

22.

Yu J, Zhu T, Wang Z et al (2007) A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer. Clin Cancer Res 13(24):7296–7304CrossRefPubMed

23.

Vinci S, Giannarini G, Selli C et al (2011) Quantitative methylation analysis of BCL2, hTERT, and DAPK promoters in urine sediment for the detection of non-muscle-invasive urothelial carcinoma of the bladder: a prospective, two-center validation study. Urol Oncol 29(2):150–156. doi:10.1016/j.urolonc.2009.01.003 CrossRefPubMed

24.

Reinert T (2012) Methylation markers for urine-based detection of bladder cancer: the next generation of urinary markers for diagnosis and surveillance of bladder cancer. Adv Urol 2012:503271. doi:10.1155/2012/503271 CrossRefPubMedPubMedCentral

25.

Scher MB, Elbaum MB, Mogilevkin Y et al (2012) Detecting DNA methylation of the BCL2, CDKN2A and NID2 genes in urine using a nested methylation specific polymerase chain reaction assay to predict bladder cancer. J Urol 188(6):2101–2107. doi:10.1016/j.juro.2012.08.015 CrossRefPubMed

26.

Costa VL, Henrique R, Danielsen SA et al (2011) TCF21 and PCDH17 methylation: an innovative panel of biomarkers for a simultaneous detection of urological cancers. Epigenetics 6(9):1120–1130. doi:10.4161/epi.6.9.16376 CrossRefPubMed

27.

Ward DG, Baxter L, Gordon NS et al (2016) Multiplex PCR and next generation sequencing for the non-invasive detection of bladder cancer. PLoS One 11(2):e0149756. doi:10.1371/journal.pone.0149756 CrossRefPubMedPubMedCentral

28.

Hernández S, López-Knowles E, Lloreta J et al (2006) Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol 24(22):3664–3671. doi:10.1200/JCO.2005.05.1771 CrossRefPubMed

29.

Burger M, van der Aa MN, van Oers JM et al (2008) Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study. Eur Urol 54(4):835–843. doi:10.1016/j.eururo.2007.12.026 CrossRefPubMed

30.

van Oers JM, Wild PJ, Burger M et al (2007) FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours. Eur Urol 52(3):760–768. doi:10.1016/j.eururo.2007.01.009 CrossRefPubMed

31.

Dueñas M, Martínez-Fernández M, García-Escudero R et al (2015) PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors. Mol Carcinog 54(7):566–576. doi:10.1002/mc.22125 CrossRefPubMed

32.

Knowles MA, Hurst CD (2015) Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer 15(1):25–41. doi:10.1038/nrc3817 CrossRefPubMed

33.

Rebouissou S, Hérault A, Letouzé E et al (2012) CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma. J Pathol 227(3):315–324. doi:10.1002/path.4017 CrossRefPubMed

34.

Kim PH, Cha EK, Sfakianos JP et al (2015) Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder. Eur Urol 67(2):198–201. doi:10.1016/j.eururo.2014.06.050 CrossRefPubMed

35.

Iyer G, Hanrahan AJ, Milowsky MI et al (2012) Genome sequencing identifies a basis for everolimus sensitivity. Science 338(6104):221. doi:10.1126/science.1226344 CrossRefPubMedPubMedCentral

36.

Singh D, Chan JM, Zoppoli P et al (2012) Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 337(6099):1231–1235. doi:10.1126/science.1220834 CrossRefPubMedPubMedCentral

37.

Wu YM, Su F, Kalyana-Sundaram S et al (2013) Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov 3(6):636–647. doi:10.1158/2159-8290.CD-13-0050 CrossRefPubMedPubMedCentral

38.

Majewski IJ, Mittempergher L, Davidson NM et al (2013) Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing. J Pathol 230(3):270–276. doi:10.1002/path.4209 CrossRefPubMed

39.

Williams SV, Hurst CD, Knowles MA (2013) Oncogenic FGFR3 gene fusions in bladder cancer. Hum Mol Genet 22(4):795–803. doi:10.1093/hmg/dds486 CrossRefPubMed

40.

Di Stefano AL, Fucci A, Frattini V et al (2015) Characterization, and inhibition of FGFR-TACC fusions in IDH wild-type glioma. Clin Cancer Res 21(14):3307–3317. doi:10.1158/1078-0432.CCR-14-2199 CrossRefPubMedPubMedCentral

41.

Carneiro BA, Elvin JA, Kamath SD et al (2015) FGFR3-TACC3: a novel gene fusion in cervical cancer. Gynecol Oncol Rep 13:53–56. doi:10.1016/j.gore.2015.06.005 CrossRefPubMedPubMedCentral

42.

Kurobe M, Kojima T, Nishimura K et al (2016) Development of RNA-FISH assay for detection of oncogenic FGFR3-TACC3 fusion genes in FFPE samples. PLoS One (in press)

43.

Redelman-Sidi G, Glickman MS, Bochner BH (2014) The mechanism of action of BCG therapy for bladder cancer–a current perspective. Nat Rev Urol 11(3):153–162. doi:10.1038/nrurol.2014.15 CrossRefPubMed

44.

Kawai K, Miyazaki J, Joraku A (2013) Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine. Cancer Sci 104(1):22–27. doi:10.1111/cas.12075 CrossRefPubMed

45.

Saint F, Patard JJ, Maille P et al (2002) Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer. J Urol 167(1):364–367CrossRefPubMed

46.

Watanabe E, Matsuyama H, Matsuda K et al (2003) Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette-Guérin immunotherapy for carcinoma in situ of the bladder. Cancer Immunol Immunother 52(8):481–486. doi:10.1007/s00262-003-0384-9 CrossRefPubMed

47.

Kumar A, Dubey D, Bansal P et al (2002) Urinary interleukin-8 predicts the response of standard and low dose intravesical bacillus Calmette-Guerin (modified Danish 1331 strain) for superficial bladder cancer. J Urol 68(5):2232–2235. doi:10.1097/01.ju.0000032140.56365.52 CrossRef

48.

Thalmann GN, Sermier A, Rentsch C et al (2000) Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin. J Urol 164(6):2129–2133CrossRefPubMed

49.

Sakai S, Kawamura I, Okazaki T et al (2010) PD-1-PD-L1 pathway impairs Th1 immune response in the late stage of infection with Mycobacterium bovis bacillus Calmette-Guérin. Int Immunol 22(12):915–925. doi:10.1093/intimm/dxq446 CrossRefPubMed

50.

Inman BA, Sebo TJ, Frigola X et al (2007) PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer 109(8):1499–1505. doi:10.1002/cncr.22588 CrossRefPubMed

51.

Vandeveer AJ, Fallon JK, Tighe R et al (2016) Systemic immunotherapy of non-muscle invasive mouse bladder cancer with avelumab, an anti-PD-L1 immune checkpoint inhibitor. Cancer Immunol Res 4(5):452–462. doi:10.1158/2326-6066.CIR-15-0176 CrossRefPubMed

52.

Powles T, Eder JP, Fine GD et al (2014) MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515(7528):558–562. doi:10.1038/nature13904 CrossRefPubMed

53.

Rosenberg JE, Hoffman-Censits J, Powles T et al (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387(10031):1909–1920. doi:10.1016/S0140-6736(16)00561-4 CrossRefPubMed

54.

Cancer Genome Atlas Research Network (2014) Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507(7492):315–322. doi:10.1038/nature12965 CrossRef

55.

Choi W, Porten S, Kim S et al (2014) Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25(2):152–165. doi:10.1016/j.ccr.2014.01.009 CrossRefPubMedPubMedCentral

56.

Damrauer JS, Hoadley KA, Chism DD et al (2014) Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci USA 111(8):3110–3115. doi:10.1073/pnas.1318376111 CrossRefPubMedPubMedCentral

57.

Choi W, Czerniak B, Ochoa A et al (2014) Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. Nat Rev Urol 11(7):400–410. doi:10.1038/nrurol.2014.129 CrossRefPubMed

Title: Biomarkers for precision medicine in bladder cancer
Authors: Takahiro Kojima
Koji Kawai
Jun Miyazaki
Hiroyuki Nishiyama
Publication date: 01-04-2017
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 2/2017
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-016-1068-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2017

Biphasic decline in renal function after radical cystectomy with urinary diversion

Recent progress and perspectives on prostate cancer biomarkers

Risk scores as useful predictors of perioperative complications in patients with rectal cancer who received radical surgery

Combined antitumor effect of γ-secretase inhibitor and ABT-737 in Notch-expressing non-small cell lung cancer

A comparison of clinical outcomes between three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for prostate cancer

Fractionated stereotactic radiotherapy for metastatic brain tumors that recurred after gamma knife radiosurgery results in acceptable toxicity and favorable local control

Keynote webinar | Spotlight on antibody–drug conjugates in cancer